Can Price Transparency Contribute to More Affordable Patient Access to Medicines?

Affordable patient access to medicines, particularly to new premium-priced medicines, is an issue, even in high-income countries.The pharmaceutical industry has argued in favour of price discrimination amongst countries based on confidential discounts as a solution to ensuring affordability and availability in less-resourced countries.In this editorial, we explain why we disagree, and we elaborate on why price transparency can contribute to affordable patient access to medicines.